Skip to main content

Main navigation

EN BM 中文

EN BM 中文

Utama

Utama
Memahami

Memahami
Mengesan

Mengesan
Merawat

Merawat
Pematuhan Rawatan

Pematuhan Rawatan
OSD

OSD
Mengawal

Mengawal
EN BM 中文

Hubungi Kami

SANTEN PHARMA MALAYSIA

(1117719-T)
Unit #23-A-10, Q Sental 2, Kuala Lumpur Sentral,
50470 Kuala Lumpur, MALAYSIA
Tel : +603-2276 3333
Fax: +603-2276 1333

Hak milik © 2022 Santen Pharma Malaysia Sdn. Bhd. Hakcipta Terpelihara.

Penolakan
Perundangan
Polisi Perlindungan Data Peribadi
Hubungi Kami

*1 National Eye Institute – Glaucoma Facts, 2016
*2 Asia Pacific Glaucoma Guideline, 2008
*3 Glaucoma Research Foundation – Understanding and Living with Glaucoma, 2016
*4 Baudouin C. et al. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthal. 2008; 86: 716-726
*5 Bpyd K. McKinney JK. “Who is at Risk for Glaucoma?”. American Academy of Ophthalmology. 2015. Web July 12, 2016.
*6 Glaucoma Research Foundation – Care and Treatment
*7 Prevent Blindness. 2016. Available from: www.preventblindness.org/living-glaucoma
*8 Weinreb RN, et al. The pathophysiology and treatment of glaucoma, a review. JAMA. 2014;311(8):1901-1911.
*9 US National Library of Medicine. National Institutes of Health.
*10 Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59 Suppl(Suppl1):S93–S96.
*11 G.F. Schwartz, H.A. Quigley. Adherence and persistence with glaucoma therapy Surv. Ophthalmol., 53 (Suppl 1) (2008), pp. S57-S68
*12 Br J Ophthalmol. 2007 Nov; 91(11): 1422–1424.
*13. Ramli, N., Supramaniam, G., Samsudin, A., Juana, A., Zahari, M., & Choo, M. M. (2015). Ocular Surface Disease in Glaucoma. Optometry and Vision Science, 92(9), e222–e226. https://doi.org/10.1097/opx.0000000000000542
*14. Leung, E. W., Medeiros, F. A., & Weinreb, R. N. (2008). Prevalence of Ocular Surface Disease in Glaucoma Patients. Journal of Glaucoma, 17(5), 350-355. doi:10.1097/ijg.0b013e31815c5f4f
*15. Barisic, F. (2014). Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications. Journal of Clinical & Experimental Ophthalmology, 05(02). doi:10.4172/2155-9570.1000334
*16. The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). (2007). The Ocular Surface, 5(2), 93-107. doi:10.1016/s1542-0124(12)70082-4
*17. Erb, C., Gast, U., & Schremmer, D. (2008). German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Archive for Clinical and Experimental Ophthalmology, 246(11), 1593-1601. doi:10.1007/s00417-008-0881-9
*18. Freeman, P. D., & Kahook, M. Y. (2009). Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Review of Ophthalmology, 4(1), 59–64. https://doi.org/10.1586/17469899.4.1.59
*19. Cristina, C. M., Simona, B., & Mirela, T. (2015). PRESERVATIVES FROM THE EYE DROPS AND THE OCULAR SURFACE. Romanian Journal of Ophthalmology, 59(1), January-March 2015, 2-5.
*20. Thygesen, J. (2018, April 13). Glaucoma therapy: Preservative-free for all?: OPTH. Retrieved from https://www.dove press.com/glaucoma-therapy-preservative-free-for-all-peer-reviewed-article-OPTH
*21. Pharmaceuticals, S. (2018, December 29). Glaucoma and the Burden of Ocular Surface Disease. Retrieved from https://the ophthalmologist.com/subspecialties/glaucoma-and-the-burden-of-ocular-surface-disease